With the flourishing development of precision medicine,theranostics,generally recognized as the integration of diagnosis and treatment,has emerged as a prominent trend in clinical research.However,theranostics primari...With the flourishing development of precision medicine,theranostics,generally recognized as the integration of diagnosis and treatment,has emerged as a prominent trend in clinical research.However,theranostics primarily emphasizes the end result of integration,without providing sufficient details on how precise diagnosis and synergetic individualized treatment could be achieved and what clinical challenges could be effectively addressed in clinical practice.Molecular probe technology provides a robust method to bridge the gap between theory and practice.Through meticulous design of the chemical structure,imaging labels or drugs were conjugated to tumor-targeting peptides,antibodies,or inducers to form molecular probes,which allow a seamless switch between targeted intervention and targeted imaging with consistency in time,space,and biodistribution.Thus,this review proposes a concept called“molecular eye”,which refers to a comprehensive system for precise diagnosis and treatment of major clinical diseases based on molecular probe technology.This medical system emphasizes the chemical basis of probe development and optimization,which can provide precise actionable information for clinical decision making,allow molecular-targeted therapy,expand the indications of old therapy,and accelerate the regulatory approval of molecular drugs.“Molecular eye”resembles the piercing eye of the Monkey King,which can detect previously“invisible”diseases and facilitate disease diagnosis,treatment,real-time evaluation,and pathology research,guiding drug development.The emergence of the“molecular eyes”will provide opportunities and challenges in the fields of clinical practice and medical research and propel the progression of contemporary medicine toward precision medicine.展开更多
Because the UT （ultrasonic testing） flexible probe technology may be an appropriate answer to examine components with uneven surface, AREVA has developed an industrial application of the CEA＇s （French Atomic Energ...Because the UT （ultrasonic testing） flexible probe technology may be an appropriate answer to examine components with uneven surface, AREVA has developed an industrial application of the CEA＇s （French Atomic Energy and Alternative Energies） flexible phased arrays sensors. As a ＂first of a kind＂ project, the challenges faced were significant, including developing a phased array smart probe suitable for industrial use on rather simple but large scale geometries, permitting UT propagation within a constraining media structure and then targeting a qualification according to ENIQ （European Network for Inspection Qualification） methodology. A prototype flexible probe, designed for UT validation, and final flexible linear array probes permitting the UT behavior （as, e.g., detection and sizing from diffraction type echoes） to be maintained on wavy coupling surfaces, have been manufactured. These probes include a profilemeter with optical sensors control and a specifically designed coupling circuit （avoiding probe housing tightness issues）. Qualification has been performed using open test blocks, （where known ＂defects＂ exist, for procedure qualification）, and blind test blocks, （where ＂defects＂ are unknown, for qualification of testing personnel）. One open test bloc was customized to represent a ＂real＂ surface condition, with gaps up to 2.5 mm under the regular rigid probes. AREVAI/BGSI in Germany was selected to lead the project, with assistance in development and manufacturing sub-contracted to ＂CEA/LIST＂ laboratory, and the companies ＂IMASONIC＂ and ＂M2M＂. This paper describes the development of these probes and explains a few features （ENIQ qualification objectives fulfilled, UT data acquired on actual perturbed surface） that made their industrial implementation successful.展开更多
基金supported by the National Natural Science Foundation of China(12275135)Jiangsu Province University Natural Science Research Project(21KJB350015)Nanjing Medical University High Level Talent Introduction Research Initiation Fund(NMUR20210003).
文摘With the flourishing development of precision medicine,theranostics,generally recognized as the integration of diagnosis and treatment,has emerged as a prominent trend in clinical research.However,theranostics primarily emphasizes the end result of integration,without providing sufficient details on how precise diagnosis and synergetic individualized treatment could be achieved and what clinical challenges could be effectively addressed in clinical practice.Molecular probe technology provides a robust method to bridge the gap between theory and practice.Through meticulous design of the chemical structure,imaging labels or drugs were conjugated to tumor-targeting peptides,antibodies,or inducers to form molecular probes,which allow a seamless switch between targeted intervention and targeted imaging with consistency in time,space,and biodistribution.Thus,this review proposes a concept called“molecular eye”,which refers to a comprehensive system for precise diagnosis and treatment of major clinical diseases based on molecular probe technology.This medical system emphasizes the chemical basis of probe development and optimization,which can provide precise actionable information for clinical decision making,allow molecular-targeted therapy,expand the indications of old therapy,and accelerate the regulatory approval of molecular drugs.“Molecular eye”resembles the piercing eye of the Monkey King,which can detect previously“invisible”diseases and facilitate disease diagnosis,treatment,real-time evaluation,and pathology research,guiding drug development.The emergence of the“molecular eyes”will provide opportunities and challenges in the fields of clinical practice and medical research and propel the progression of contemporary medicine toward precision medicine.
文摘Because the UT （ultrasonic testing） flexible probe technology may be an appropriate answer to examine components with uneven surface, AREVA has developed an industrial application of the CEA＇s （French Atomic Energy and Alternative Energies） flexible phased arrays sensors. As a ＂first of a kind＂ project, the challenges faced were significant, including developing a phased array smart probe suitable for industrial use on rather simple but large scale geometries, permitting UT propagation within a constraining media structure and then targeting a qualification according to ENIQ （European Network for Inspection Qualification） methodology. A prototype flexible probe, designed for UT validation, and final flexible linear array probes permitting the UT behavior （as, e.g., detection and sizing from diffraction type echoes） to be maintained on wavy coupling surfaces, have been manufactured. These probes include a profilemeter with optical sensors control and a specifically designed coupling circuit （avoiding probe housing tightness issues）. Qualification has been performed using open test blocks, （where known ＂defects＂ exist, for procedure qualification）, and blind test blocks, （where ＂defects＂ are unknown, for qualification of testing personnel）. One open test bloc was customized to represent a ＂real＂ surface condition, with gaps up to 2.5 mm under the regular rigid probes. AREVAI/BGSI in Germany was selected to lead the project, with assistance in development and manufacturing sub-contracted to ＂CEA/LIST＂ laboratory, and the companies ＂IMASONIC＂ and ＂M2M＂. This paper describes the development of these probes and explains a few features （ENIQ qualification objectives fulfilled, UT data acquired on actual perturbed surface） that made their industrial implementation successful.
